Humacyte announces results in high-risk dialysis from V007 Pivotal Phase 3

Humacyte (HUMA) “announced that its abstract on the V007 Pivotal Phase 3 clinical trial of the acellular tissue engineered vessel in arteriovenous access for high-risk patients with end-stage renal disease was accepted for an oral presentation at the Society for Vascular Surgery Vascular Annual Meeting. The abstract titled “Acellular Tissue Engineered Vessel Outperforms Arteriovenous Fistula in High-Risk Patients on Hemodialysis: Results from the CLN-PRO-V007 Randomized Controlled Trial” will be presented at the VAM25 meeting in New Orleans this Friday, June 6, 2025.”